A
Asim Alsaedi
Researcher at King Saud bin Abdulaziz University for Health Sciences
Publications - 27
Citations - 531
Asim Alsaedi is an academic researcher from King Saud bin Abdulaziz University for Health Sciences. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 6, co-authored 18 publications receiving 371 citations. Previous affiliations of Asim Alsaedi include King Abdulaziz Medical City & National Guard Health Affairs.
Papers
More filters
Journal ArticleDOI
Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial
Yaseen M. Arabi,Yaseen M. Arabi,Yaseen M. Arabi,Adel Alothman,Adel Alothman,Hanan H. Balkhy,Hanan H. Balkhy,Abdulaziz Al-Dawood,Abdulaziz Al-Dawood,Sameera Aljohani,Sameera Aljohani,Shmeylan Al Harbi,Shmeylan Al Harbi,Suleiman Kojan,Suleiman Kojan,Majed Al Jeraisy,Majed Al Jeraisy,Ahmad M. Deeb,Ahmad M. Deeb,Abdullah M. Assiri,Fahad Al-Hameed,Fahad Al-Hameed,Asim Alsaedi,Asim Alsaedi,Yasser Mandourah,Ghaleb A. Almekhlafi,Nisreen Murad Sherbeeni,Fatehi Elnour Elzein,Javed Memon,Yusri Taha,Abdullah Almotairi,Khalid Maghrabi,Ismael Qushmaq,Ali Al Bshabshe,Ayman Kharaba,Sarah Shalhoub,Jesna Jose,Robert A. Fowler,Robert A. Fowler,Frederick G. Hayden,Mohamed A. Hussein +40 more
TL;DR: The aim of this study is to investigate the efficacy of treatment with a combination of lopinavir/ritonavir and recombinant IFN-β1b provided with standard supportive care in patients with laboratory-confirmed MERS requiring hospital admission.
Journal ArticleDOI
Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial.
Yaseen M. Arabi,Yaseen M. Arabi,Ayed Y. Asiri,Abdullah M. Assiri,Hani Jokhdar,Adel Alothman,Adel Alothman,Hanan H. Balkhy,Hanan H. Balkhy,Sameera Aljohani,Sameera Aljohani,Shmeylan Al Harbi,Shmeylan Al Harbi,Suleiman Kojan,Suleiman Kojan,Majed Al Jeraisy,Majed Al Jeraisy,Ahmad M. Deeb,Ahmad M. Deeb,Ziad A. Memish,Ziad A. Memish,Sameeh S. Ghazal,Sarah Al Faraj,Fahad Al-Hameed,Fahad Al-Hameed,Asim Alsaedi,Asim Alsaedi,Yasser Mandourah,Ghaleb A. Al Mekhlafi,Nisreen Murad Sherbeeni,Fatehi Elzein,Abdullah Almotairi,Ali Al Bshabshe,Ayman Kharaba,Jesna Jose,Abdulrahman Al Harthy,Mohammed Al Sulaiman,Ahmed Mady,Ahmed Mady,Robert A. Fowler,Robert A. Fowler,Frederick G. Hayden,Abdulaziz Al-Dawood,Abdulaziz Al-Dawood,Mohamed Abdelzaher,Wail Bajhmom,Mohamed A. Hussein,Mohamed A. Hussein +47 more
TL;DR: The aim of this article is to describe the statistical analysis plan for the MIRACLE trial, which is the first randomized controlled trial for MERS treatment, and the primary outcome is 90-day mortality.
Journal ArticleDOI
Machine learning and deep learning methods that use omics data for metastasis prediction
Somayah Albaradei,Somayah Albaradei,Maha A. Thafar,Maha A. Thafar,Asim Alsaedi,Asim Alsaedi,Christophe Van Neste,Takashi Gojobori,Magbubah Essack,Xin Gao +9 more
TL;DR: A review of machine learning and deep learning-based metastasis prediction methods can be found in this paper, where different types of molecular data are used to build the models and the critical signatures derived from the different methods.
Journal ArticleDOI
High contribution and impact of resistant gram negative pathogens causing surgical site infections at a multi-hospital healthcare system in Saudi Arabia, 2007-2016.
Aiman El-Saed,Aiman El-Saed,Aiman El-Saed,Hanan H. Balkhy,Hanan H. Balkhy,Hanan H. Balkhy,Majid Alshamrani,Majid Alshamrani,Sameera Aljohani,Asim Alsaedi,Wafa Al Nasser,Ayman El Gammal,Saad A. Almohrij,Ziyad Alyousef,Sara Almunif,Mohammad Alzahrani +15 more
TL;DR: GNPs in a tertiary care setting in Saudi Arabia are responsible for more than 60% of SSI with more resistant patterns than Western countries, and these patterns are significantly more frequent than in NHSN hospitals.
Journal ArticleDOI
A project to reduce the rate of central line associated bloodstream infection in ICU patients to a target of zero
Muhammad Yaseen,Fahad Al-Hameed,Khalid Osman,Mansour Al-Janadi,Majid Alshamrani,Asim Alsaedi,Abdulhakeem O. Althaqafi +6 more
TL;DR: A multidisciplinary team was created to improve the compliance to the CL bundle which was expected to have an impact on the rate ofCLABSI to achieve zero CLABSI events and the ultimate target of zero CLA BSI was achieved in the year 2014 and maintained in theyear 2015 with a sustained compliance of 100% to theCL Bundle.